Table 2 Summary of demographic and clinical characteristics of HIV-infected participants stratified by pulmonary disease status.

From: HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension

Characteristic

Statistic

Normotensive

Pulmonary hypertensive

Total

Gender

Male

n (%)

19 (59%)

13 (41%)

32 (82%)

Female

n (%)

4 (57%)

3 (43%)

7 (17%)

Ethnicity

African-American

n (%)

8 (38%)

6 (37%)

14 (37%)

Caucasian

n (%)

9 (42%)

10 (62%)

19 (51%)

Other

n (%)

4 (19%)

–

4 (10%)

CD4 counts

Asymptomatic

n (%)

21 2(91%)

12 (75%)

33 (84%)

AIDS

n (%)

2 (8%)

4 (25%)

6 (15%)

Antiretroviral therapy

Naïve

n (%)

5 (21%)

2 (12%)

7 (17%)

Experienced

n (%)

18 (78%)

14 (87%)

32 (82%)

HIV viral loads

Viremic

n (%)

13 (56%)

9 (56%)

22 (56%)

Suppressed

n (%)

10 (43%)

7 (43%)

17 (43%)

Hemodynamics

mean PAP (by RHC)

Mean ± SD

18.20 ± 2.8

36.06 ± 11.9

 

Mean PASP (by echo)

Mean ± SD

33.57 ± 6.4

51.19 ± 23.5

 
  1. We grouped the research subjects enrolled into this study as per the following criteria: pulmonary normotensive (mPAP < 25 mm Hg by RHC or PASP by echocardiography if RHC was not performed), pulmonary hypertensive (mPAP > 25 mm Hg by RHC or PASP by echocardiography if RHC was not performed); asymptomatic for HIV disease (CD4 counts > 200 cells/ul); AIDS (CD4 counts < 200 cells/ul); antiretroviral treatment naïve if they reported having no experience with antiretroviral therapy any time on or before enrollment into this study; viremic if patient had HIV viral loads > 40 copies/ml at sampling time or 6 months before and; suppressed if patient had HIV viral loads < 40 copies/ml at sampling time or 6 months before.
Back to article page